業績

2012年度 :: 学会発表 :: 国際学会 :: 業績

European Association for the Study of the Liver(EASL 2012).
2012.4. Barcelona, Spain

<Poster>
Karino Y, Nakajima Y, Ozeki I, Toyata J, Imamura M, Tsuge M, Chayama K, Akuta N, Suzuki F, Kumada H.
2250 mg/day of telaprevir dosage impare the ribavirin dosage and clinical effect of triple therapy in the patients with a low total clearance of ribavirin.

Digestive Disease Week 2012 (DDW 2012).
2012.5. San Diego, USA

<Oral Presentation>
Hayashi T, Kawakami H, Osanai M, Ishiwatari H, Naruse H, Hisai H, Yanagawa N, Kaneto H, Koizumi K, Sakurai T.
A multicenter, prospective, randomized, controlled trial to determine the efficacy of endoscopic sphincterotomy prior to self-expandable metallic stent placement for unresectable pancreatic cancer patients: the essence trial in hokkaido.

Kato M, Kikuchi S, Asaka M, for the Japan Gast Study Group.
Long-term follow-up study about preventive effect of H. pylori eradication for the incidence of metachronous gastric cancer after endoscopic resection of primary early gastric cancer.

Natsuizaka M, Naganuma S, Kagawa S, Whelan K, Ohashi S, Chang S, Klein-Szanto AJ, Gimotty PA, Diehl JA, Herlyn M, Nak-agawa H.
A functional interplay between TGF-β and Notch signaling determines esophageal cancer cell fates.

Natsuizaka M, Sanders C, Kagawa S, Naganuma S, Ohashi S, Whelan K, Wong GS, Maria EV, Rhim AD, Diehl JA, Herlyn M, Nakagawa H.
CD44 defines a highly plastic esophageal squamous cancer cells with a tumor initiating capability.

Natsuizaka M, Nakagawa K, Naganuma S, Kinugasa H, Subramanian H, Xinjun J, Stephen AL, Klein-Szanto AJ, Diehl JA, Rustgi AK, Nakagawa H.
Hypoxia induces IGFBP3 by HIF-1α-dependent transcription through a novel hypoxia-response element and privileged mRNA translation in the polysomes.

Sasahira N, Isayama H, Kawakami H, Ito Y, Matsubara S, Ishiwatari H, Uebayashi M, Uchino R, Yagioka H, Togawa O, Tada N, Sakamoto N, Kato J, Koike K.
Can early double guidewire technique facilitate common bile duct cannulation and reduce post ERCP pancreatitis? -results of a multicenter prospective randomized controlled Trial: education trial-

<Poster>
Isayama H, Kawakubo K, Kato H, Itoi T, Kawakami H, Hanada K, Ishiwatari H, Yasuda I, Kawamoto H, Itokawa F, Kuwatani M, Iiboshi T, Hayashi T, Doi S, Nakai Y.
A multicenter retrospective study of endoscopic ultrasound-guided biliary drainage (EUS-BD) for malignant biliary obstruction in japan.

Kawakami H, Kuwatani M, Kawakubo K, Haba S, Kudo T, Abe Y, Sakamoto N.
A novel endoscopic approach to severe strictures of the biliary or main pancreatic duct using a diathermic sheath.

Kawakubo K, Kawakami H, Kuwatani M, Haba S, Kudo T, Abe Y, Sakamoto N.
A newly designed large cell stent for endoscopic bilateral stent-in-stent placement in patients with malignant hilar biliary obstruction.

Kawakubo K, Kawakami H, Kuwatani M, Haba S, Kudo T, Abe Y, Sakamoto N.
Endoscopic nasobiliary drainage; complications and long-term outcomes.

Kuwatani M, Kawakami H, Sakamoto N.
Efficacy of antispasmodic drugs for endoscopic ultrasonography - interim analysis of a multicenter prospective randomized con-trolled trial.

Mabe K, Kato M, Nojima M, Tanuma T, Yao K.
An educational lecture on the VSCS improves the accuracy of magnifying endoscopy with narrow-band imaging for diagnosis of early gastric cancer and routine-practice VSCS-based ME-NBI helps maintain diagnostic performance. r

Ohnishi S, Takeda H, Muto S, Nakagawa K, Sadakane C, Nahata M, Saegusa Y, Hattori T, Asaka M.
A study on gender differences in feeding behavior and plasma acyl ghrelin levels in aged mice following exposure to a novel envi-ronmental stress.

Ryozawa S, Isayama H, Maetani I, Nakai Y, Kawakami H, Yasuda I, Mochizuki H, Iwano H, Maguchi H, Kida M, Kubota K, Mukai T, Hasebe O, Igarashi Y, Hanada K, Irisawa A, Itoi T, Ito K, Kogure H.
A prospective multicenter study of a fully-covered metal stent in patients with distal malignant biliary obstruction: WATCH-2 study.

Sato T, Akaike J, Toyota J, Karino Y, Ohmura T.
Efficacy of endoscopic injection sclerotherapy for rectal varices.

Togawa O, Kwakami H, Isayama H, Mohri D, Kawakubo K, Hamada T, Nakai Y, Kogure H, Sakamoto N, Koike K, Kita H.
A prospective feasibility study of preoperative biliary drainage using fully-covered self-expandable metallic stent for pancreatic head cancer.

Yasuda I, Nakashima M, Iwai T, Isayama H, Itoi T, Hisai H, Inoue H, Kato H, Kanno A, Kubota K, Irisawa A, Igarashi H, Okabe Y, Kitano M, Kawakami H, Hayashi T, Mukai T, Kida M, Shimosegawa T.
Japanese multicenter experience of endoscopic necrosectomy for infected walled-off pancreatic necrosis: the JENIPaN study.

BMS Seminar.
2012.5. Daejeon, Korea

<Oral Presentation>
Karino Y.
Nucleoside analog therapy in chronic hepatitis B.

American Society of Clinical Oncology 2012
2012.6. Chicago, USA

<Poster>
Yuki S, Komatsu Y, Miyagishima T, Kato T, Hatanaka K, Nakamura M, Kudo M, Akakura N, Tateyama M, Sakata Y.
Phase II trial of combined chemotherapy with Irinotecan,S-1, and bevacizumab(IRIS/Bev) in patients with metastatic colorectal cancer -Updated analysis-. Hokkaido gastrointestinal cancer study group(HGCSG) trial.

10th Asian Clinical Oncology Society.
2012.6. Seoul, Korea

<Oral Presentation>
Kobayashi Y, Komatsu Y, Hayashi H, Kawamoto Y, Nakatsumi H, Yuki S, Okada H, Tsuji Y, Hatanaka K, Koike M, Kato T, Nakamura M, Miyagishima T, Sato Y, Takahashi Y, Ota T, Nagasako T, Muto S, Hisai H, Konno J, Sakata Y.
Retrospective cohort study on the safety and efficacy of panitumumab for metastatic colorectal cancer patients : The HGCSG1002 study - Analysis of after cetuximab refractory -

<Poster>Kudo M, Yuki S, Komatsu Y, Miyagishima T, Kato T, Hatanaka K, Nakamura M, Akakura N, Tateyama M, Sakata Y.

Phase II trial of combined chemotherapy with Irinotecan, S-1, and bevacizumab(IRIS/Bev) in patients with metastatic colorectal cancer-Updated analysis-. Hokkaido gastrointestinal cancer study group(HGCSG) trial.

25th International Workshop on Helicobacter and related bacteria in chronic digestive inflammation and gastric cancer (EHSG 2012).
2012.9. Ljubljana, Slovenia

<Poster>
Kato M, Murakami K, Furuta T.
A randomized controlled study for the third-line rescuer therapy after failure of two H. pylori eradication in Japan.

Mabe K, Ohno M, Ishigaki S, Suzuki M, Takahashi M, Ono S, Shimizu Y, Kato M, Asaka M.
Multi-center study of gastric cancers detected after Helicobacter pylori eradication.

11th World Congress for the Esophageal Disease
2012.9. Como, Italy

<Poster>
Shimizu Y, Takahashi M, Yoshida T, Ono S, Mabe K, Kato M, Honma A, Oridate N, Asaka M.
Screening examination for superficial head and neck cancer in patients who underwent endoscopic resection for squamous cell carcinoma of the esophagus.

18th International Symposium on Endoscopic Ultrasonography (EUS 2012).
2012.9. Saint Petersburg, Russia

<Poster>
Haba S, Kawakami H, Kuwatani M, Kawakubo K, Kudo T, Abe Y, Hirano S, Sakamoto N.
EUS-FNA for preoperative diagnosis of pancreatic cancer.

37th European Society for Medical Oncology.
2012.9. Vienna, Austria

<Poster>
Yuki S, Shitara K, Takahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Oze I, Muro K.
Preliminary safety data from a randomized phase II study comparing dose-escalated weekly paclitaxel versus standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.

Fukushima H, Kobayashi Y, Sasaki T, Doi A, Naruse H, Meguro T, Hisai H, Kato S, Iwai K, Komatsu Y.
Retrospective cohort study on the safety and efficacy of panitumumab for metastatic colorectal cancer patients: The HGCSG1002 study -Comparison between anti-EGFR antibody na?ve patients and cetuximab pretreated patients-

Hatanaka K, Yuki S, Miyagishima T, Kato T, Nakamura M, Kudo M, Tateyama M, Asaka M, Sakata Y, Komatsu Y.
Phase II trial of combined chemotherapy with Irinotecan, S-1, and bevacizumab(IRIS/Bev) in patients with metastatic colorectal cancer -Updated analysis-. Hokkaido gastrointestinal cancer study group(HGCSG) trial.

Yoshino T, Yuki S, Yamazaki K, Machida N, Komatsu Y, Oyama R, Yachi Y, Onuma H, Ohtsu A.
Phase 1b study of a novel oral PPARγ agonist, efatutazone in combination with FOLFIRI in japanese patients with metastatic colo-rectal cancer who failed the first-line therapy.

Shinozaki E, Bando H, Yoshino T, Nishina T, Kadowaki S,Yamazaki K, Yuki S, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A.
Clinical outcome of cetuximab for metastatic colorectal cancer patients harboring any KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA mutations.

Amano T, Shimada Y, Nishina T, Shinozaki K, Esaki T, Komatsu Y, Shimozuma K, Akita H, Ohashi Y, Frederick H.
Prospective validation of patient neurotoxicity questionnaire (PNQ) for assessment of oxaliplatin neurotoxicity: CSP-HOR 16.

19th International Meeting on Hepatitis C Virus & Related Viruses.
2012.10. Venice, Italy

<Poster>
Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD, Cheng JC.
Let-7b is a novel regulator of hepatitis C virus replication.

The 6th Meeting of the Society of Gastrointestinal Intervention (SGI2012).
2012.10. Seoul, Korea

<Oral Presentation>
Yamamoto N, Isayama H, Kawakami H, Sasahira N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Sasaki T, Ito Y, Nakai Y, Kuwatani M, Hirano K, Tada M, Koike K.
A new fully-covered metal stent designed for the treatment of pancreatic fluid collection.

<Poster>
Kuwatani M, Kawakami H, Onodera M, Kawakubo K, Haba S, Kudo T, Abe Y, Hirano S, Sakamoto N.
Endoscopic ultrasound-guided transmural drainage for pancreatic fistula or pancreatic surgery.

20th United European Gastroenterology Week.
2012.10. Amsterdam, Netherland

<Poster>
Kato M, Haneda M, Ishigaki S, Suzuki M, Takahashi M, Ono S, Mabe K, Shimizu Y.
The identification for high risk group of gastric cancer using serum pepsinogen after successful eradication of H.pylori.

Mabe K, Ishigaki S, Akakura N, Sugai N, Konno Y, Katsuki S, Suzuki A, Kubota K, Kato M, Sakamoto N.
Significant association of intestinal spirochaetosis with sessile serrated adenoma/polyp.

Sato T, Akaike J, Toyota J, Karino Y, Ohmura T.
Treatments for colorectal variceal bleeding with portal hypertension.

The 10th Single Topic Conference (JSH STC 2012).
2012.11. Tokyo, Japan

<Poster>
Hige S, Karino Y, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Ozeki I, Sato T, Ohmura T, Toyota J.
Factors related to the discontinuation of triple therapy with PEG-IFN, ribavirin and telaprevir for cases with chronic hepatitis C.

63th Annual Meeting of American Association for the Study of Liver Diseases.
2012.11. Boston, USA

<Poster>
Karino Y, Hige S, Ozeki I, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J.
Telaprevir induced renal dysfunction leads to an early elevation of serum RBV concentration in triple therapy.

Karino Y, Nakajima T, Hige S, Ozeki I, Kimura M, Arakawa T, Kuwata Y, Sato T, Ohmura T, Toyota J.
Excessive dosage of telaprevir promotes anemia through a high blood concentration of telaprevir and renal function disorder in triple therapy.

Kusano-Kitazume A, Sakamoto N, Okuno Y, Mori K, Nakagawa M, Kakinuma S, Nitta S, Murakawa M, Azuma S, Nishi-mura-Sakurai Y, Tanaka E, Hagiwara M, Asahina Y, Watanabe M.
Antiviral effetcts and action mechanism of novel N- (morpholine-4-carbonyloxy) amidine compounds against hepatitis C virus.

Asahina Y, Murakawa M, Sakamoto N, Kakinuma S, Nakagawa M, Azuma S, Nishimura-Sakurai Y, Nitta S, Kusano-Kitazume A, Watanabe M.
Impaired IL28B gene induction a nd poor IL28B promoter activity influenced by the IL28B minor allele are closely associated with a null response to interferon in chronic hepatitis C patients.

Itsui Y, Sakamoto N, Suda G, Yauchi T, Watanabe M.
Antiviral effect of novel interferon-inducible proteins, GBP-1 and IFI-27, against hepatitis C virus replication.

Asian Pacific Digestive Week 2012 (APDW 2012).
2012.12. Bangkok, Thailand

<Satellite symposium>
Kato M.
NSAID/Aspirin induced small intestinal injury.

Gastrointestinal Cancers Symposium (ASCO-GI).
2013.1. San Francisco, USA

<Poster>
Yuki S, Komatsu Y, Fukushima H, Sasaki T, Amano T, Miyagishima T, Hatanaka K, Nakamura M, Tateyama M, Sakata Y.
Phase II trial of combined chemotherapy with Irinotecan, S-1, and bevacizumab(IRIS/Bev) in patients with metastatic colorectal cancer -Final analysis-. Hokkaido gastrointestinal cancer study group(HGCSG) trial.

Kobayashi Y, Fukushima H, Sasaki T, Yuki S, Okuda H, Kusumi T, Doi A, Tsuji Y, Hatanaka K, Uebayashi M, Koike M, Kato T, Nakamura M, Sato Y, Ohta T, Kudo M, Konno J, Iwai K, Sakata Y, Komatsu Y.
Retrospective cohort study on the safety and efficacy of panitumumab for metastatic colorectal cancer patients: The HGCSG1002 study - Analysis of after cetuximab refractory-.

Dazai M, Fukushima H, Sato Y, Yuki S, Ohnuma H, Okuda H, Tsuji Y, Kawamoto Y, Hatanaka K, Iwanaga I, Koike M, Kato T, Nakamura M, Sogabe S, Fujikawa K, Ho-sokawa A, Hisai H, Tateyama M, Sakata Y, Komatsu Y.
Retrospective cohort study on the safety and efficacy of panitumumab for metastatic colorectal cancer patients :HGCSG1002 -Analysis of adverse events -.

Takahari D, Shitara K, Yuki S, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Matsuo K, Oze I, Muro K.
Randomized phase II study comparing dose-Escalated weekly Paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).

Iwanaga I, Yuki S, Fukushima H, Ishiguro A, Takahata T, Miyagishima T, Kudo M, Uehata Y, Sakata Y, Komatsu Y.
An open, multi-center, phase II clinical trial to evaluate efficacy and safety of S-1 plus split Cisplatin in patients with advanced gastric cancer(AGC). - HGCSG0702 : Safety analysis.

Nakamura M, Yuki S, Dazai M, Kobayashi Y, Kato T, Naruse H, Kudo M, Akakura N, Sakata Y, Komatsu Y.
Phase II trial of combined chemotherapy with Irinotecan, S-1, and bevacizumab(IRIS/Bev) in patients with metastatic colorectal cancer (mCRC) : Hokkaido gastrointestinal cancer study group(HGCSG) trial. - Comparison of the efficacy of KRAS status -.

Sogabe S, Fukushima H, Yuki S, Kobayashi Y, Miyagishima T, Okuda H, Kusumi T, Doi A, Tsuji Y, Kawamoto Y, Ehira N, Koike M, Meguro T, Takahashi Y, Yoshizaki K, Muto S, Ishiguro A, Kato S, Sakata Y, Komatsu Y.
Retrospective cohort study on the safety and efficacy of panitumumab (Pmab) for metastatic colorectal cancer (mCRC) patients: The HGCSG1002 study - Analysis of clinical early predictor for the efficacy -.

Sugimoto N, Tanaka J, Tsuda M, Okamoto W, Okuda H, Imamura H, Shimokawa T, Sakai D, Kurokawa Y, Komatsu Y, Ishioka C, Tsujinaka T, Takiuchi H, Furukawa H.
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HER-BIS-1).

Mizuno N, Yamao K, Komatsu Y, Munakata M, Ishiguro A, Yamaguchi T, Ohkawa S, Kida M, Ioka T, Takeda K, Kudo T, Kitano M, Iguchi H, Tsuji A, Ito T, Ta naka M, Furuse J, Hamada C, Sakata Y.
Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer.

>